Even-Chen Oren, Barak Segev
School of Psychological Sciences, Tel Aviv University, 69978, Tel Aviv, Israel.
Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Eur J Neurosci. 2019 Aug;50(3):2552-2561. doi: 10.1111/ejn.14133. Epub 2018 Sep 12.
Fibroblast growth factor 2 (FGF2) is a member of the FGF-family, which consists of 22 members, with four known FGF receptors (five in humans). Over the last 30 years, FGF2 has been extensively studied for its role in cell proliferation, differentiation, growth, survival and angiogenesis during development, as well as for its role in adult neurogenesis and regenerative plasticity. Over the past decade, FGF2 has been implicated in learning and memory, as well as in several neuropsychiatric disorders, including anxiety, stress, depression and drug addiction. In this review, we present accumulating evidence indicating the involvement of FGF2 in neuroadaptations caused by drugs of abuse, namely, amphetamine, cocaine, nicotine and alcohol. Moreover, evidence suggests that FGF2 is a positive regulator of alcohol and drug-related behaviors. Thus, although additional studies are yet required, we suggest that reducing FGF2 activity may provide a novel therapeutic approach for substance use disorders.
成纤维细胞生长因子2（FGF2）是FGF家族的成员之一，该家族由22个成员组成，已知有四种FGF受体（人类有五种）。在过去30年里，FGF2因其在发育过程中的细胞增殖、分化、生长、存活和血管生成中的作用，以及在成体神经发生和再生可塑性中的作用而受到广泛研究。在过去十年中，FGF2与学习和记忆以及几种神经精神疾病有关，包括焦虑、应激、抑郁和药物成瘾。在这篇综述中，我们展示了越来越多的证据，表明FGF2参与了由滥用药物（即苯丙胺、可卡因、尼古丁和酒精）引起的神经适应性变化。此外，有证据表明FGF2是酒精和药物相关行为的正向调节因子。因此，尽管还需要更多的研究，但我们认为降低FGF2的活性可能为物质使用障碍提供一种新的治疗方法。
